ABSTRACT
As the cost of developing new drugs keeps escalating and the chance of bringing them to market shows a worrisome decreasing trend, the ef‚cient use of information in clinical drug development is increasingly critical to the success, and even survival, of the pharmaceutical industry. A variety of methods can be included under the broad combination of information class, such as meta-analyses, multiregional trials, and bridging studies. In this chapter, we’ll focus on the last but will also discuss brie©y the other two cited approaches in Section 5.4.
